Učitavanje...
Individualised benefit–harm balance of aspirin as primary prevention measure – a good proof-of-concept, but could have been better…
Guidelines from different organisations regarding the use of aspirin for primary prevention vary despite being based on similar evidence. Translating these in practice presents a further major challenge. The benefit–harm balance tool developed by Puhan et al. (BMC Med 13:250, 2015) for aspirin can o...
Spremljeno u:
| Izdano u: | BMC Med |
|---|---|
| Glavni autor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4936221/ https://ncbi.nlm.nih.gov/pubmed/27383519 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-016-0648-9 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|